Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 6/20 | 0.54 |
| ▸ | KIF5B | P33176 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | ETV6 | P41212 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | CCDC6 | Q16204 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | NPM1 | P06748 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGR | P09769 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181909 | 0.89 | FYN (0.58) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL8992897 | 0.76 | FYN (0.41) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL30521695 | 0.75 | FYN (1.00) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL18613401 | 0.75 | FYN (1.00) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4177792 | 0.75 | LCK (0.65) | KDRLCKSRCKMT2ANPC1 | |
| SCHEMBL4167319 | 0.73 | FYN (0.67) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4173636 | 0.69 | NPC1 (0.57) | FYNKDRMAPTALDH1A1LCK | |
| SCHEMBL4168118 | 0.69 | FYN (0.53) | FYNKDRMAPTLCKSRC | |
| SCHEMBL9219353 | 0.69 | MAPT (0.56) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4175110 | 0.68 | NPC1 (0.71) | FYNKDRMAPTALDH1A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | claimed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | claimed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | claimed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | FYN 360/4885RET 252/4885KIF5B 1372/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885RET 166/4885KIF5B 1833/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885RET 166/4885KIF5B 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.